INTRODUCTION
The cyclin kinase inhibitor p27 kip1 is one of the most frequently dysregulated tumor suppressor proteins in human cancers. Its expression levels closely correlate with the overall prognosis of the affected patient (Porter et al., 2006) . In strong contrast to other tumor suppressor proteins, the p27 kip1 genomic locus is rarely mutated in cancer cells, indicating that transcriptional and posttranscriptional mechanisms are responsible for the reduction of p27 kip1 expression (Philipp-Staheli et al., 2001) . Since the discovery of skp2 as the essential F box protein that as part of the SCF E3 ubiquitin ligase controls p27 kip1 stability, several examples of an inverse correlation between skp2 and p27 kip1 expression in different tumors have been published. Some studies have even shown that tissues from tumors that express low levels of p27 kip1 , i.e., colon carcinoma, mantle cell lymphoma, small-cell lung cancer, and others, also display an increase in p27 kip1 -degradatory activity (Ben-Izhak et al., 2003; Osoegawa et al., 2004) . Moreover, a number of molecular treatments like the inhibition of the EGF or ErbB2 receptors, either by inhibitory antibodies or small-molecule drugs, result in increased expression of the p27 kip1 protein (Lenferink et al., 2000) . Together, these findings suggest that an increase in p27 kip1 expression levels should prevent tumor cell proliferation. To test this possibility,
SIGNIFICANCE
In this work, we identify an antitumoral drug, argyrin A, which acts by stabilizing the cyclin kinase inhibitor p27 kip1 . Due to increased turnover, p27 kip1 is not sufficiently expressed in many human cancers, and therefore targeting the p27 kip1 degradation machinery might prove beneficial in the treatment of a variety of human malignancies. We also show that p27 kip1 belongs to a group of critical substrates that mediate the biological effects of proteasome inhibition. In addition to identifying a p27 kip1 -stabilizing compound, our work improves the understanding of proteasome-regulated processes under normal and pathophysiological conditions.
we recently created a mouse model in which the proteolytic turnover of p27 kip1 is partly blocked through a mutation in a p27 kip1 phosphorylation site that is critical for ubiquitin-dependent proteasomal turnover (p27T187A) (Malek et al., 2001) . When these mice are challenged with a carcinogen (ENU), they develop a variety of tumors with no apparent difference in tumor spectrum compared to wild-type mice. Importantly, however, expression of p27T187A significantly reduces the number of intestinal adenomatous polyps that progress to invasive carcinomas (Timmerbeul et al., 2006) . This study therefore showed that preventing p27 kip1 degradation could be beneficial in the treatment or prevention of intestinal cancer.
Based on these studies, we set out to identify substances that would reduce or block p27 kip1 turnover, thereby allowing re-expression of the protein in tumor tissues.
RESULTS

A Cell-Based Screening Assay Identifies Argyrin A as a Compound that Prevents p27
kip1 Degradation To identify substances that lead to an increase in the expression levels of p27 kip1 , we generated a high-throughput assay system based on the stable expression of a p27 kip1 -GFP fusion protein in human cells (see Experimental Procedures for details). One of the substances that exerted the strongest increase in fluorescence was identified as argyrin A, a cyclical peptide that had originally been identified as a metabolic product derived from the myxobacterium Archangium gephyra (Sasse et al., 2002) ( Figure 1A ). The time-course experiment displayed in Figure 1B shows that argyrin A induced an increase in cellular p27 kip1 levels in HCT116, SW480, and HeLa cells. To determine whether the argyrin A-induced change in p27 kip1 expression levels was due to an increase in its stability, we measured the half-life of p27 kip1 in HeLa and SW480 cells in the presence and absence of argyrin A. Figure 1C shows a quantification of the expression levels of p27 kip1 compared to actin in cycloheximide-treated cells that were incubated with argyrin A or left untreated. While p27 kip1 had a half-life of 4 hr (SW480) or 9 hr (HeLa) in untreated cells, addition of argyrin A blocked the turnover of p27 kip1 completely. These results indicate that argyrin A treatment results in an increase in endogenous p27 kip1 levels by preventing the turnover of the protein.
As all known p27 kip1 turnover mechanisms involve proteolytic destruction of the protein by the 20S proteasome (Montagnoli et al., 1999; Sutterluty et al., 1999) , we next measured the activity of purified human proteasomes after incubation with increasing amounts of argyrin A. Figure 2A shows that incubation of purified human 20S proteasome with argyrin A in vitro led to a dose-dependent inhibition of the caspase-, trypsin-and chymotrypsinlike proteasome activities. Importantly, the extent of proteasome inhibition by argyrin A was comparable to that measured with the clinically used proteasome inhibitor bortezomib (Velcade). In agreement with the ability of argyrin A to inhibit the proteasome, we found that other well-known proteasome substrates, namely p53, p21, Bax, and NF-kB, also accumulated in response to argyrin A treatment ( Figure 2B ). Next we analyzed the cellular effects of argyrin A treatment using a panel of different cell lines. As shown by flow cytometry, argyrin A exerted two different cellular phenotypes ( Figure 2C ). Primary human fibroblasts and A549 and HCT116 cells ceased to proliferate, whereas SW480 and CaCo as well as MCF7 and HeLa cells underwent apoptosis as shown by a dramatic increase in the sub-G1 phase fraction ( Figure 2C ; see also Figure S1A available online).
Argyrin A-Induced Apoptosis in Tumor Cells Requires the Stabilization of p27 kip1
We recently demonstrated that p27 kip1 stabilization prevents progression from adenomatous polyps to invasive intestinal cancers (Timmerbeul et al., 2006) . We therefore tested whether argyrin A-induced p27 kip1 stabilization would be beneficial in the treatment of human colon cancer cell-derived tumor xenografts. We first tested whether argyrin A was active in vivo. After (C) SW480 and HeLa cells were treated with argyrin A or left untreated for 12 hr, after which cycloheximide was added at a concentration of 25 mg/ml. The expression levels of p27 kip1 were determined at the indicated time points by western blotting and normalized against actin expression, which was used as an internal control. The graph shows a quantification of three independent experiments. Error bars represent SD.
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Pharmacological Targeting of p27   kip1 intraperitoneal injection of argyrin A, 20S proteasome was isolated from peripheral blood lymphocytes at different time points after injection. As shown in Figure 3A , argyrin A inhibited all proteasome activities. While the maximum inhibitory activity was reached between 24 hr and 48 hr postinjection, all activities returned to baseline levels after 72 hr. Based on this finding, we injected tumor-bearing mice every 3 days with argyrin A (0.15 mg/kg body weight). As shown in Figure 3B , argyrin A led to a significant reduction in the size of the xenotransplanted tumors used in these experiments. The extent and kinetics of tumor regression were comparable to or even more pronounced than that observed in the bortezomib-treated animals. Importantly, however, we did not observe any signs of discomfort, weight loss ( Figure 3C ), or disease in the argyrin A-treated animals compared to the bortezomib-treated animals. To assay the extent of proteasome inhibition, the induction of p27 kip1 , and the development of apoptotic cell death in primary tumor tissue, we treated tumor-bearing mice with a single dose of argyrin A or bortezomib and explanted tumors at the indicated time points thereafter. As shown in Figure 3D , both bortezomib and argyrin A treatments led to a significant reduction of proteasome activity in the primary tumor tissue. Importantly, argyrin A treatment resulted in induction of p27 kip1 and apoptotic cell death in more than 60% of all tumor cells ( Figures 3E and 3F ).
Next we tested whether the stabilization of p27 kip1 was required for the biological functions associated with argyrin A by an increase in the sub-G1 fraction ( Figure 4A ; Figure S1B ). The same response was observed with MG132 treatment (data not shown). In strong contrast, argyrin A treatment induced apoptosis in cells that expressed p27 kip1 while only 10% of p27 kip1 knockout fibroblasts underwent apoptotic cell death after 60 hr of treatment. These differences in sensitivity in response to argyrin A treatment were not due to differences in the accumulation of other proteasomal substrates in p27 kip1 wild-type and knockout cells, as p53 and p21 levels increased in both cell lines in response to argyrin A ( Figure 4B ). To extend this observation to human cancer cells, we reduced the levels of p27 kip1 in HeLa cells using p27 kip1 -specific siRNA. As shown in Figure 4C , HeLa cells expressing p27 kip1 underwent apoptosis in response to argyrin A after 48 hr of treatment, while cells in which the expression of p27 kip1 was reduced by pretreatment with p27 kip1 siRNA were protected against the apoptosis-inducing function of this compound.
To gain more insight into the molecular mechanism by which p27 kip1 induces apoptosis in response to argyrin A treatment, we tested whether this process depends on the cyclin kinase inhibitory function of the p27 kip1 protein.
To answer this question, we used embryonic fibroblasts derived from a p27 kip1 knockin mouse strain that expresses a mutant form of p27 kip1 that cannot bind cyclin/cdk complexes (p27C-K-) (Besson et al., 2007) . Treatment of these cells or wild-type control cells with argyrin A led to the induction of p27 kip1 expression (Figures S1C and S1D) and apoptosis ( Figure 4D ). However, suppression of p27 kip1 expression by siRNA pretreatment protected p27C-KMEFs against the apoptosis-inducing activity of argyrin A (Figure 4E ). These data indicate that the apoptosis-inducing function A) Mice were injected intraperitoneally with argyrin A (0.03 mg/kg body weight) or bortezomib (1 mg/kg body weight). At the indicated time points, 20S proteasome was isolated from peripheral blood cells and the activity of the different proteasome subunits was determined as described in Figure 2A. (B) SW480 colon carcinoma cell lines mixed with Matrigel were injected under the skin of nu/nu mice to establish xenotransplant tumors. Treatment with argyrin A or bortezomib was begun when these tumors reached a volume of 200 mm 3 . The graph shows a quantification of tumor volumes at the indicated time points compared to the starting size, which was set as 100. n = 8 argyrin A (0.15 mg/kg body weight); n = 4 bortezomib (0.6 mg/kg body weight); n = 10 PBS/EtOH control.
(C) All mice were weighed throughout the course of the experiment. The graph shows the changes in body weight for mice treated with argyrin A versus bortezomib.
(D) Determination of proteasome activity in tumor tissue after treatment with bortezomib and argyrin A. After a one-time injection of the respective compounds, tumors were explanted at the indicated time points and proteasomes were extracted from the tumor tissue. The activity of the respective proteasome subunits was determined as described in Figure 2A . 
Pharmacological Targeting of p27 kip1 of p27 kip1 in response to proteasome inhibition is independent of its well-characterized function as a cyclin kinase inhibitor.
Proteasome inhibition by argyrin A leads to the stabilization of several different proteins ( Figure 2B ) that might be involved in the induction of apoptosis in an additive or synergistic manner with p27 kip1 . Caspase-3, for example, is itself a substrate of the proteasome and a well-known inducer of cell death in response to proteasome inhibition (Suzuki et al., 2001) . We therefore asked whether caspase-3 activation is required for the argyrin A-induced and p27 kip1 -mediated induction of cell death. As shown in Figure 4F , treatment of HeLa cells with argyrin A led to an increase in caspase-3 activity as compared to untreated control cells. Loss of caspase-3 by siRNA treatment protected cells against the apoptosis-inducing activity of argyrin A ( Figure 4F ) without significantly affecting the levels of p27 kip1 ( Figure 4G ).
Loss of p27 kip1 in turn prevented the activation of caspase-3 in response to argyrin A treatment ( Figure 4F ). This experiment establishes caspase-3 as a downstream effector of p27 kip1 -mediated cell death.
While these results point to a central role of p27 kip1 in mediating the apoptosis-inducing function of argyrin A, they do not exclude the possibility that other proteasome-regulated proteins exist that might act in parallel to p27 kip1 . We therefore tested the importance of IkBa and c-Myc stabilization for the induction of apoptosis in response to argyrin A treatment. The expression of both proteins is controlled by proteasome-mediated degradation, both proteins are regulators of central survival pathways, and both have also been shown to be involved in the control of bortezomib-induced cell death (Adams, 2004a (Adams, , 2004b Nikiforov et al., 2007) . As shown in Figures S2A and S2B , neither c-Myc nor IkBa knockdown led to a significant reduction in the number of apoptotic MCF7 breast cancer cells after argyrin A treatment. In summary, these results show that the ability of argyrin A to induce apoptosis in tumor cells depends on the expression of the tumor suppressor protein p27 kip1 . Interestingly, this profound effect is independent of the cyclin kinase inhibitory function of p27 kip1 but involves the activation of caspase-3. While these data point to a central function of p27 kip1 in mediating argyrin A-induced cell death, they do not exclude the possibility of parallel independent pathways of equal importance.
Argyrin A-Induced p27 kip1 Stabilization Prevents
Neovascularization and Damages Existing
Tumor Blood Vessels Next we tested whether argyrin A would also show an effect against HCT116-derived tumor xenografts, as these cell lines did not undergo apoptosis in vitro but instead arrested in the G1 phase. While the reduction in tumor size was not as pronounced as in SW480-derived xenotransplants, we still observed a significant reduction after treatment with argyrin A ( Figure 5A ). Interestingly, when SW480-or HCT116-derived tumors were explanted, they uniformly showed a large necrotic area in the center of the tumor that was filled with blood and necrotic tumor tissue ( Figure 5B ). This phenotype is often observed with drugs that interfere with blood vessel formation or compounds that directly damage existing tumor vessels (Tozer et al., 2005) . To analyze this phenotype in greater detail, we first asked whether argyrin A was able to prevent the formation of capillary-like tube structures formed by human umbilical vein endothelial cells (HUVECs) on Matrigel, an assay frequently used to test the ability of a compound to interfere with neovascularization (Maffucci et al., 2005) . Figure 5C shows a quantification of the relative length of capillary tubes formed by HUVECs upon stimulation with vascular endothelial growth factor (VEGF). The addition of argyrin A led to a 40% reduction in tube formation in this assay. We then asked whether, in analogy to the results observed for the induction of apoptosis in transformed cells, a reduction of p27 kip1 expression levels would protect endothelial cells against the inhibitory activity of argyrin A. Indeed, when HUVECs were transfected with siRNA against p27 kip1 before argyrin A was added, an almost complete rescue of tube length was observed. The effects exerted by bortezomib in this assay were smaller and were not rescued by loss of p27 kip1 . In addition to tube length, we also quantitated the number of blood vessellike structures formed by HUVECs after treatment with argyrin A or bortezomib ( Figure 5D ). Both treatments led to a significant reduction in vessel-like structures. However, loss of p27 kip1 only had a significant effect on the argyrin A-induced phenotype, reinforcing the notion that argyrin A exerts its biological functions through an increase in p27 kip1 expression. In line with previous observations (Roccaro et al., 2006) showing that proteasome inhibition leads to a reduction in VEGF secretion, we found that both drugs induced an approximately 40% reduction in the expression of VEGF by endothelial cells, which was at least partially rescued by the loss of p27 kip1 ( Figure 5E ). While the reduction in VEGF levels can contribute to the observed antitumoral effects in vivo, the relatively strong increase in VEGF secretion after ablation of p27 kip1 by siRNA also suggests that p27 kip1 might control the expression levels of VEGF independently of mechanisms affected by proteasome inhibition. The formation of a necrotic area in the center of a tumor can also be caused by agents that directly target the preexisting tumor vasculature. We therefore determined the microvessel density in tumor tissues (SW480 or HCT116) from mice that received a single injection of argyrin A. Figure 6A shows that argyrin A leads to the induction of p27 kip1 expression in CD31-positive endothelial cells as early as 90 min after injection. The increased expression of p27 kip1 correlated with a striking reduction of cells that stained positive for CD31, with only about 10% of the positive cells remaining at 72 hr after injection ( Figure 6B ). Reduction in CD31 staining can be caused by destruction of the endothelial cells or by loss of endothelial function. To understand this phenotype in greater detail, we analyzed primary tumor material by electronic microscopy. As early as 90 min after injection, we observed swelling of endothelial cells that was followed by a loss of basal membrane attachment and cell-cell contacts (Figure 6C ) at later time points. As a result, many of the examined tumor blood vessels were occluded with endothelial cells or erythrocytes. The destruction of the tumor core that we observed after argyrin A treatment might therefore be a result of thrombotic occlusion of the affected blood vessels. In contrast, the bortezomib-induced reduction in CD31-positive cells correlated with the appearance of apoptotic endothelial cells ( Figure 6C ). While many vessel-damaging agents exert their effects through a tubulin-stabilizing activity (Tozer et al., 2005) , argyrin A interferes with the ability of the endothelial cell to adhere to the basal membrane. We therefore tested whether argyrin A could also reduce the ability of cultured endothelial cells to form focal adhesions.
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Pharmacological Targeting of p27   kip1 As shown in Figure 6D , staining of human endothelial cells with paxillin antibodies showed a significant reduction in the number of focal adhesions in argyrin A-treated cells as compared to untreated cultures. The reduction in paxillin staining was accompanied by a reduced formation of stress fibers, which were visualized through staining of cultured endothelial cells with antibodies specific for actin. Importantly, both the loss of focal adhesions and the loss of stress fiber formation were reverted when p27 kip1 expression was reduced with p27 kip1 -specific siRNA before argyrin A was added to the medium.
Stress fiber formation and expression of focal adhesions are both processes regulated through activation of RhoA signaling (Leung et al., 1996; Ridley and Hall, 1992) . RhoA activity was therefore directly measured through the use of antibodies that detect the Ser3-phosphorylated form of cofilin, a well-characterized downstream target of RhoA signaling (Besson et al., 2004) . Figure 6E shows that treatment with argyrin A reduced the amount of phosphorylated cofilin, while treatment with siRNA against p27 kip1 restores the expression of phosphorylated cofilin completely.
Previous work (Read et al., 1995) had shown that proteasome inhibition due to a reduction in NF-kB activity can also affect in- tegrin signaling, which results in a reduced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). As shown in Figures S3A and S3B , treatment of HUVECs with argyrin A or bortezomib led to a reduction in VCAM-1 and ICAM-1 expression, a process that was rescued by the siRNA-mediated suppression of IkBa expression. Interestingly, however, the expression of these proteins was still reduced in argyrin A-treated cells in which p27 kip1 expression was reduced by siRNA ( Figures S3C and S3D ). These results indicate that the loss of p27 kip1 is sufficient to rescue argyrin A-induced changes in cell adhesion despite the inactivation of other central signaling pathways. We conclude that argyrin A exerts its effects on preexisting blood vessels through the stabilization of p27 kip1 in endothelial cells, which correlates with an inhibition of RhoA signaling. Loss of RhoA signaling induces reduced formation of stress fibers, a reduction in the phosphorylation of downstream effectors, and reduced formation of focal adhesions. These molecular changes provide an explanation for the occlusion of tumor blood vessels in vivo, which resulted in complete destruction of the core of the tumor. 
Pharmacological Targeting of p27   kip1 transformed cells, prevents neovascularization, and leads to a loss of adherence of tumor endothelial cells. All of these activities depend on the expression of p27 kip1 , while loss of this protein confers resistance to argyrin A treatment. Nevertheless, we found the molecular mechanism by which argyrin A exerts its p27 kip1 -stabilizing activity to be the inhibition of the 20S proteasome, a multiprotein complex that is involved in the destruction of the majority of all cellular proteins. Moreover, the well-known and clinically used proteasome inhibitor bortezomib showed no specificity for p27 kip1 and also differed in its in vitro and in vivo activities from those observed with argyrin A. We therefore decided to directly test the extent to which the cellular effects of proteasome inhibition per se are influenced by p27 kip1 expression. To this end, we designed specific siRNA molecules that target the b1 (caspase-like activity), b2 (trypsinlike activity), and b5 (chymotrypsin-like activity) subunits of the mouse 20S proteasome. We then reduced the expression of these subunits in embryonic fibroblasts derived from wild-type or p27 kip1 knockout cells and measured proteasome activity and cell-cycle distribution. Figures 7A and 7C show activity measurements for the caspase-, chymotrypsin-, and trypsinlike activities of the proteasome after treatment with argyrin A or a combination of siRNAs against the b1, b2, and b5 subunits in p27 kip1 wild-type or knockout cell lines. Importantly, the degree of proteasome inhibition we achieved with siRNA-mediated knockdown of proteasomal subunits was comparable to the effects exerted by argyrin A or bortezomib treatment in vivo (cf. Figure 3A) . The levels of proteasome subunit expression are displayed in the corresponding western blots.
Loss of proteasome activity in wild-type fibroblasts led to the induction of apoptosis in approximately 35% (argyrin A) or 45% (siRNA) of all cells after 24 hr ( Figure 7B ). Importantly, only 5% (argyrin A) or 6% (siRNA) of all fibroblasts derived from p27 kip1 knockout mice underwent apoptosis at comparable levels of proteasome inhibition ( Figure 7D ), while treatment of wild-type or p27 kip1 knockout cells with bortezomib induced massive apoptosis independent of p27 kip1 status (cf. Figure 4A ). These results point toward an as yet unrecognized role of p27 kip1 as a critical regulator of apoptotic cell death in response to proteasome inhibition. To understand in greater detail the mechanisms that make argyrin A-induced cell death dependent upon p27 kip1 expression, we decided to compare the cellular responses of cells treated with argyrin A versus bortezomib directly. One way to obtain information on the reaction of a cell toward an external perturbation is to determine the gene expression signature of that cell in response to the perturbation (Lamb et al., 2006) . To this end, we determined the gene expression signatures of MCF7 cells in response to argyrin A, bortezomib, or b1,2,5 siRNA and compared the resulting gene expression profiles. Figure 7E shows a Pearson correlation plot of the gene expression data that we obtained in these experiments using untreated or argyrin A-, bortezomib-, or siRNA-treated MCF7 cells. Figure S4A shows the corresponding proteasome activity measurements in MCF7 cells, and Figure S4C shows the correlation values. As shown in Figure 7E , the gene expression profiles of MCF7 cells treated with bortezomib versus argyrin A differ dramatically. While bortezomib treatment led to changes in the expression of more than 10,900 genes (Table S1 ), only about 500 genes (Table S2) changed in response to argyrin A treatment. Among these genes, 311 were affected by both bortezomib and argyrin A. The functional gene clustering based on their corresponding gene ontology terms (Tables S3A-S3C) indicates that while argyrin A and bortezomib both inhibit the 20S proteasome, they cause very divergent perturbations at the cellular level. From these data, (E) Heat map displaying a correlation analysis of genome-wide gene expression profiles of MCF7 breast cancer cells treated with argyrin A, bortezomib, or siRNA against the b1,2,5 subunits of the proteasome for the indicated amounts of time. The corresponding correlation value matrix is given in Figure S4B .
(F) Number of apoptotic MCF7 cells after transfection with siRNA specific for the b1,2,5 subunits of the proteasome or combined treatment with siRNA and argyrin A or bortezomib. The corresponding proteasome activity measurements are given in Figures S4D and S4E .
we conclude that bortezomib treatment affects additional targets in the cell that result in the activation of various cellular responses that make bortezomib-induced cell death independent of p27 kip1 expression. In a second set of experiments, we compared the gene expression profiles of argyrin A-and siRNA-mediated knockdown of proteasome subunits at comparable levels of proteasome inhibition (Figures S4B and S5 ; Table S7 ). These experiments revealed that siRNA-mediated proteasome inhibition, like argyrin A treatment, led to very limited alterations in the gene expression profiles of MCF7 cells (Tables S4 and S5) , with approximately 30% of the regulated genes overlapping between argyrin A-and siRNA-treated cells ( Figure S6 ; Table S6 ). This result indicates that both types of treatment result in few off-target effects. The limited degree of overlap between siRNAand argyrin A-treated cells may reflect the differences in acute inhibition of proteasome activity by a chemical compound as compared to the reduction in proteasome subunit transcription by siRNA treatment. Our gene expression studies also revealed no evidence for the expression of gene sets associated with the activation of the ER-stress response that has been observed in cells treated with bortezomib (Obeng et al., 2006) (Figure S7 ).
Finally, we decided to directly test whether the biological activities we observed with argyrin A and bortezomib are at least in part independent of their ability to inhibit the proteasome. To answer this question experimentally, we compared the effects of bortezomib and argyrin A treatment in MCF7 breast cancer cells with cells in which the activity of the proteasome had first been reduced by siRNA-mediated knockdown of the b1, b2, and b5 subunits and which were then treated with argyrin A or bortezomib. Figure 7F shows that argyrin A treatment of cells with reduced proteasome activity did not lead to a significant increase in proteasome inhibition (cf. Figures S4D and S4E for proteasome activity measurements) or in the number of apoptotic cells. Addition of bortezomib to MCF7 cells with reduced proteasome activity also did not increase the level of proteasome inhibition but did result in a >50% increase in the number of apoptotic cells as compared to ''pure'' proteasome inhibition. These data support the conclusion that bortezomib has cellular effects other than proteasome inhibition that contribute to its biological function.
DISCUSSION
Using a combination of in vitro and in vivo studies, we define three mechanisms by which argyrin A influences tumor cell proliferation, all of which depend on the stabilization of p27 kip1 . By inducing apoptosis, argyrin A can target the tumor cell itself. Previous work pointed to an apoptosis-inducing function of p27 kip1 overexpression in tumor cells (Katayose et al., 1997; Katner et al., 2002; Wang et al., 1997; Zhang et al., 2005) ; however, the molecular mechanism by which p27 kip1 causes cell death is largely unknown. Gene expression profiles of argyrin A-treated MCF7 cells revealed the induction of genes that are involved in the release of cytochrome c from the mitochondria, pointing toward a role of the endogenous apoptosis pathway (Table S3A) . Importantly, however, the apoptosis-inducing function of argyrin A was entirely dependent on the expression of p27 kip1 , as neither cells derived from p27 kip1 knockout mice nor cells in which p27 kip1 expression was abolished through siRNA responded to the compound. Nevertheless, p27 kip1 does not induce apoptosis directly but requires the activation of downstream effectors such as caspase-3. The molecular mechanism by which p27 kip1 exerts this function is unknown. Surprisingly, however, it does not involve its cyclin kinase inhibitory activity, as cells expressing a non-cdk-binding version of the protein still undergo cell death when treated with argyrin A. This observation is not without precedence, however, as the cyclin kinase inhibitor p57 kip2 was recently shown to promote apoptosis by activating the intrinsic pathway in response to chemotherapies independently of its cyclin kinase inhibitory function (Vlachos et al., 2007) . Our observations therefore add to a growing body of evidence attributing additional functions to the p27 kip1 protein that are not regulated by the classical cyclin kinase inhibitory activity (Besson et al., 2007; Nguyen et al., 2006; Vernon and Philpott, 2003) . Not all tumor cells that were treated with argyrin A in vitro underwent apoptosis; some instead ceased to proliferate and underwent cell-cycle arrest. A reduction in the proliferative fraction of a tumor is not necessarily beneficial, as quiescent cells are often resistant to chemotherapy or radiation treatment. We therefore tested the extent to which xenotransplanted tumors derived from cells that underwent G1 arrest in response to argyrin A in vitro would still be sensitive to the compound in vivo. We found that such tumors could also be effectively treated. The most prominent change in the tumor tissue was a complete destruction of the core of the cancer, pointing toward an antiangiogenic or vessel-damaging effect of argyrin A. In agreement with previous studies showing that overexpression of p27 kip1 in human endothelial cells through adenoviral gene transfer reduces cell proliferation (Goukassian et al., 2001 ), we found that argyrin A reduced the ability of such cells to form vessel-like structures and also reduced the expression of VEGF. This activity was again dependent on the expression of p27 kip1 , as siRNA-transfected endothelial cells became resistant toward treatment with argyrin A and restored VEGF expression. The third and most surprising antitumoral function of argyrin A is its ability to target preexisting tumor vessels directly. By studying the ultrastructural properties of argyrin A-treated tumors, we found that a single injection of argyrin A induced a loss of adherence of endothelial cells from the basal membrane, which resulted in a protrusion of these cells into the lumen of the vessels. Loss of endothelial cell adhesion was accompanied by signs of thrombosis of the affected tumor vessels. In agreement with these observations in tumor tissues, we found that argyrin A reduces the number of focal adhesions in endothelial cells in vitro by interfering with the activity of RhoA signaling. The role of RhoA in cellular adhesion has been extensively studied, and it was recently shown that p27 kip1 can control RhoA signaling directly (Besson et al., 2004) . p27 kip1 knockout cells show increased levels of RhoA activity, while re-expression of p27 kip1 inhibits downstream signaling and influences cellular functions like cell migration or adhesion. In line with these observations, we found that the ability of argyrin A to block RhoA signaling and thereby cell adhesion depends on the expression of p27 kip1 . Loss of p27 kip1 prevents RhoA inhibition by argyrin A and results in the preservation of focal adhesion and stress fiber formation.
Together, these findings show that argyrin A exerts its antitumoral activities through the stabilization of p27 kip1 . This observation is surprising given that our studies indicate that the mechanism by which argyrin A prevents p27 kip1 turnover is through the
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Pharmacological Targeting of p27   kip1 inhibition of the catalytic activities of the 20S proteasome. The proteasome inhibitory activity of argyrin A was demonstrated on purified proteasomes in vitro, in peripheral blood cells in vivo, and in proteasome derived from tumor tissue itself. It encompasses all catalytic activities and is not specific for p27 kip1 , as a number of other proteasomal substrates like p21, p53, and others are no longer degraded in cells treated with argyrin A. Surprisingly, by blocking proteasome activity with siRNA directed against catalytic proteasomal subunits, we found that p27 kip1 is indeed required for the apoptosis-inducing function of proteasome inhibition per se. While the proteasome is involved in the regulation of the majority of cellular proteins, our observations regarding the critical role of p27 kip1 imply that some proteasomal substrates are of key importance in mediating the biological effects connected with proteasome inhibition; one such key substrate is p27 kip1 . The identification of one key proteasome target leads us to speculate that other proteins of equal importance must exist that in an either additive or synergistic manner cause the different biological effects connected with proteasome inhibition. Our data show that the specificity of argyrin A for p27 kip1 is not shared by the proteasome inhibitor bortezomib. By comparing the gene expression patterns of argyrin A-and bortezomib-treated cells, we found that the cellular responses exerted by these treatments are highly divergent. Specifically, we found that bortezomib affects a multitude of additional cellular targets that result in a broader biological response of the treated cell. In fact, bortezomib treatment of cells in which the proteasome was partly inhibited through siRNA-mediated reduction in proteasome subunit expression still responded with an increase in the number of apoptotic cells without a further reduction in proteasome activity. In strong contrast, argyrin A-and siRNA-mediated reduction in proteasome activity resulted in only very limited changes in gene expression profiles. The activity and toxicity profile of clinically used inhibitors like bortezomib might therefore not result entirely from the inhibition of the proteasome but may reflect the disruption of additional cellular systems such as the induction of endoplasmic reticulum stress (Obeng et al., 2006) . Given that proteasome inhibitors have been shown to synergize with a number of chemotherapeutic or molecular drugs in vitro, it will be important to test whether the greater specificity of argyrin A will allow higher levels of proteasome inhibition at a tolerable level of toxicity.
In summary, we have identified argyrin A as a proteasome inhibitor that by preventing the destruction of the cyclin kinase inhibitor p27 kip1 exerts broad antitumoral activities. Second, we found that stabilization of p27 kip1 in addition to targeting the tumor cell itself also affects the tumor vasculature through p27 kip1 -mediated inhibition of RhoA activity. And lastly, we found that p27 kip1 belongs to a group of critical proteasomal substrates that are responsible for the biological phenotypes induced under conditions of proteasome inhibition. The unique properties of argyrin A combined with its high activity at well-tolerated levels make this compound a good candidate for further clinical development.
EXPERIMENTAL PROCEDURES
High-Throughput Screen for p27 kip1 -Stabilizing Substances
A cellular high-throughput screen for p27 kip1 -stabilizing compounds was established by stably introducing a DNA plasmid (EGFP-N1, Clontech) that allows the expression of p27 kip1 -GFP fusion protein in HeLa cells. p27 kip1 -GFP-expressing cells were selected with neomycin, and several independent clones were subcultured. HeLa p27 kip1 -GFP cells were seeded in 384-well plates (Corning) and incubated with a set of highly diverse natural products (part of the Helmholtz Center for Infection Research myxobacterial metabolite collection) at a concentration of 70 nM. GFP emission was determined by fluorometric measurements using a Victor 1420 multilabel counter (PerkinElmer) at 3 hr, 24 hr, 48 hr, and 60 hr after the start of treatment. The proteasome inhibitor MG132 was used as a positive control. All compounds used for highthroughput screening were dissolved in DMSO at a concentration of 1 mM in 96-well polypropylene microtiter plates. The Helmholtz Center for Infection Research collection of myxobacterial metabolites (Reichenbach and Hö fle, 1999) contained 120 pure compounds (>95% pure).
Antibodies, Western Blotting, Immunofluorescence, and Immunohistochemistry Immunohistochemical staining of mouse tumor tissue, western blotting, cdk2-associated kinase activity measurements, and immunofluorescence experiments were performed as described previously Timmerbeul et al., 2006) . For antibodies used in this study, refer to the Supplemental Data.
siRNA siRNA knockdown was performed using FuGENE6 or HiPerFect transfection reagent. Transfections were performed using siRNA in a concentration of 0.2 nM for Psmb1, Psmb2, PSMB1, PSMB2, CDKN1B, CASP3, NFKBIA, MYC, and p27 kip1 and in a concentration of 0.4 nM for Psmb5 and PSMB5.
Proteasome Purification and Proteasome Assays
Proteasome assays with purified 20S proteasome were performed as described previously (Lightcap et al., 2000) using erythrocyte-derived 20S proteasome (Biomol International, LP PW8720) and the fluorometric substrates Succ-LLVY-AMC, BZ-VGR-AMC, and Z-Lle-AMC (Biomol International, LP PW9905). Proteasome extraction from cells and tumor sections was performed as described previously . For proteasome extraction from whole blood, frozen whole blood cell pellets were thawed and lysed in 2-3 pellet volumes of cold lysis buffer (5 mM EDTA [pH 8.0]). Lysates were spun down at 4 C, and the supernatant was transferred to a fresh tube.
Five microliters was taken for the determination of protein concentration using a Coomassie protein assay (Pierce). Proteasome assays using proteasome purified from cells or tissues were carried out in a 100 ml reaction volume containing 20 mg proteasome extract, 50 mmol/l EDTA, and 60 mmol/l fluorogenic substrate (chymotrypsin-like [CT-L], trypsin-like [T-L], or caspase-like [C-L]) in ATP/DTT lysis buffer at 37 C. The assay buffer was supplemented with a final concentration of 0.05% SDS for the evaluation of the chymotrypsin-like activity and caspase-like activity. The rate of cleavage of fluorogenic peptide substrates was determined by monitoring the fluorescence of released aminomethylcoumarin using a Victor 1420 multilabel counter (Wallac) at an excitation wavelength of 395 nm and emission wavelength of 460 nm over a period of 60 min.
Xenotransplant Studies
All experiments were performed after review by and in accordance with the animal rights and protection agencies of Lower Saxony, Germany. 1 310 7 SW480 cells or HCT116 cells in 100 ml DMEM medium and 100 ml Matrigel were subcutaneously injected into the flanks of NMRI nu/nu mice. 
Electronic Microscopy
Small specimens of tumor were fixed in 2.5% glutaraldehyde (Polysciences) in 0.1 M sodium cacodylate (pH 7.3) and postfixed with 2% osmium tetroxide (Polysciences) in the same buffer. After dehydration in graded alcohols, specimens were embedded in Epon (Serva). Thin sections stained with uranyl acetate and lead citrate were examined in a Philips EM 301 electron microscope. The electron micrographs were selected, digitalized, and processed using Adobe Photoshop 6.0.
DNA Microarray Hybridization and Analysis
DNA microarray hybridization was performed as described previously (Pfoertner et al., 2006) . For details on data analysis, please refer to Supplemental Experimental Procedures.
Statistical Analysis
Statistical analysis was carried out using Microsoft Excel software. Unless stated otherwise, all data are presented as mean ± SD; error bars represent SD in all figures. Intergroup comparisons were performed by two-tailed Student's t test. p < 0.05 was considered statistical significant.
ACCESSION NUMBERS
The complete data set is deposited in MIAME-compliant format at the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/) and is available under the accession number GSE8565.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, seven figures, and seven tables and can be found with this article online at http://www.cancercell.org/cgi/content/full/14/1/23/DC1/.
